GlycoMimetics (GLYC) Competitors $0.16 -0.01 (-6.63%) Closing price 06/13/2025Extended Trading$0.16 0.00 (0.00%) As of 06/13/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GLYC vs. ARTV, KLTO, ATHE, ITRM, KPTI, AKTX, ACRV, CLNN, VOR, and EGRXShould you be buying GlycoMimetics stock or one of its competitors? The main competitors of GlycoMimetics include Artiva Biotherapeutics (ARTV), Klotho Neurosciences (KLTO), Alterity Therapeutics (ATHE), Iterum Therapeutics (ITRM), Karyopharm Therapeutics (KPTI), Akari Therapeutics (AKTX), Acrivon Therapeutics (ACRV), Clene (CLNN), Vor Biopharma (VOR), and Eagle Pharmaceuticals (EGRX). These companies are all part of the "pharmaceutical products" industry. GlycoMimetics vs. Its Competitors Artiva Biotherapeutics Klotho Neurosciences Alterity Therapeutics Iterum Therapeutics Karyopharm Therapeutics Akari Therapeutics Acrivon Therapeutics Clene Vor Biopharma Eagle Pharmaceuticals GlycoMimetics (NASDAQ:GLYC) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership. Is GLYC or ARTV more profitable? Artiva Biotherapeutics' return on equity of -75.95% beat GlycoMimetics' return on equity.Company Net Margins Return on Equity Return on Assets GlycoMimeticsN/A -230.74% -177.39% Artiva Biotherapeutics N/A -75.95%-39.51% Does the media favor GLYC or ARTV? In the previous week, Artiva Biotherapeutics had 1 more articles in the media than GlycoMimetics. MarketBeat recorded 1 mentions for Artiva Biotherapeutics and 0 mentions for GlycoMimetics. GlycoMimetics' average media sentiment score of 1.87 beat Artiva Biotherapeutics' score of 0.79 indicating that GlycoMimetics is being referred to more favorably in the media. Company Overall Sentiment GlycoMimetics Very Positive Artiva Biotherapeutics Positive Do analysts prefer GLYC or ARTV? Artiva Biotherapeutics has a consensus price target of $17.80, suggesting a potential upside of 1,019.50%. Given Artiva Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Artiva Biotherapeutics is more favorable than GlycoMimetics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GlycoMimetics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Artiva Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation and earnings, GLYC or ARTV? GlycoMimetics has higher earnings, but lower revenue than Artiva Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGlycoMimetics$10K1,000.25-$37.88M-$0.46-0.34Artiva Biotherapeutics$250K154.93-$65.37MN/AN/A Do insiders and institutionals hold more shares of GLYC or ARTV? 75.2% of GlycoMimetics shares are held by institutional investors. 8.7% of GlycoMimetics shares are held by company insiders. Comparatively, 21.4% of Artiva Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryArtiva Biotherapeutics beats GlycoMimetics on 8 of the 12 factors compared between the two stocks. Get GlycoMimetics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLYC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GLYC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLYC vs. The Competition Export to ExcelMetricGlycoMimeticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.00M$782.11M$5.54B$8.87BDividend YieldN/A4.84%5.39%4.10%P/E Ratio-0.341.0926.2319.90Price / Sales1,000.25219.25413.23113.66Price / CashN/A23.4436.1356.90Price / Book1.945.998.045.38Net Income-$37.88M-$27.64M$3.15B$248.50M7 Day PerformanceN/A-0.07%1.44%2.04%1 Month Performance-99.26%6.49%3.62%4.84%1 Year Performance-99.43%8.20%34.68%20.23% GlycoMimetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLYCGlycoMimetics2.031 of 5 stars$0.16-6.6%N/A-99.4%$10.00M$10K-0.3450Positive NewsHigh Trading VolumeARTVArtiva Biotherapeutics2.7095 of 5 stars$1.62+2.5%$17.80+998.8%N/A$39.47M$250K0.0081High Trading VolumeKLTOKlotho NeurosciencesN/A$1.20-22.1%N/AN/A$38.99MN/A-3.33N/ANews CoverageATHEAlterity Therapeutics2.8528 of 5 stars$4.37+4.0%$12.00+174.6%+123.2%$38.76MN/A0.0010Gap UpITRMIterum Therapeutics1.8882 of 5 stars$0.94-4.6%$9.00+852.8%-11.2%$37.78MN/A-0.9510News CoverageKPTIKaryopharm Therapeutics4.1773 of 5 stars$4.33-1.1%$43.20+897.7%-61.6%$37.41M$145.24M-0.33380News CoverageAKTXAkari Therapeutics1.6154 of 5 stars$1.16+3.6%N/A-62.7%$37.33MN/A0.009ACRVAcrivon Therapeutics3.3723 of 5 stars$1.18flat$17.71+1,401.2%-78.8%$36.99MN/A-0.5358Positive NewsCLNNClene2.8153 of 5 stars$4.10-4.2%$40.00+875.6%-40.3%$36.82M$340K-1.01100Analyst ForecastVORVor Biopharma3.9994 of 5 stars$0.29+20.7%$7.06+2,333.5%+59.3%$36.24MN/A-0.18140Analyst UpgradeAnalyst RevisionGap UpHigh Trading VolumeEGRXEagle Pharmaceuticals2.2352 of 5 stars$2.79-3.0%N/A-44.6%$36.23M$257.55M0.00100Gap Up Related Companies and Tools Related Companies Artiva Biotherapeutics Alternatives Klotho Neurosciences Alternatives Alterity Therapeutics Alternatives Iterum Therapeutics Alternatives Karyopharm Therapeutics Alternatives Akari Therapeutics Alternatives Acrivon Therapeutics Alternatives Clene Alternatives Vor Biopharma Alternatives Eagle Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLYC) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredMake 22x more from this summer’s Bitcoin boomBitcoin is on fire again. Wall Street’s piling in. ETFs are smashing volume records. And regular investors ...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlycoMimetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GlycoMimetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GLYC Stock Alerts